Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 2019

View Archived Issues

Nitric oxide-scavenging nanogel suppresses onset of rheumatoid arthritis in vivo

Cell wall component causes trouble in Lyme disease

Going down in flames improves antitumor immunity

Novel protein-coding gene is key to intestinal development

Mutations in SSBP1 gene cause a form of optic atrophy with mitochondrial depletion

Metabolic enzyme targeting takes on pulmonary hypertension

[64Cu]Cu(SarbisPSMA): a bifunctional PSMA ligand for developing PSMA-targeted theranostics

Interim analysis of phase III CASPIAN trial shows improvement in OS in patients treated with Imfinzi

Ovid Therapeutics initiates phase III NEPTUNE trial

Wave Life Sciences initiates DYSTANCE 51 phase II/III study of suvodirsen

Updated phase II data for camrelizumab combination treatment in advanced G/GEJ cancer

Phase I results for fluzoparib in combination with apatinib and paclitaxel in gastric cancer

Researchers link LIG3 mutations to mitochondrial neurogastrointestinal encephalomyopathy

Avaliv Therapeutics divulges new cathepsin D inhibitors

Arena Pharmaceuticals divulges beta3-adrenoceptor antagonists

Sage Therapeutics identifies GABA-A receptor modulators

Galapagos identifies new compounds for HBV

Array BioPharma divulges TAM receptor tyrosine kinases inhibitors

Vaccibody reports immunogenicity data from cancer patients treated with VB10.NEO

CD28 unveiled as potential therapeutic target for giant-cell arteritis

LSK BioPharma reports topline data from phase III study of rivoceranib in advanced gastric cancer

FDA approves Doptelet for chronic immune thrombocytopenia

Darzalex approved by FDA for newly diagnosed multiple myeloma ineligible for ASCT

Phase I/II LuPIN trial of [177Lu]PSMA-617 and NOX-66 in men with mCRPC shows early signs of efficacy

FDA approves Soliris for neuromyelitis optica spectrum disorder

Advaxis to close AIM2CERV trial, focus resources on neoantigen-directed immunotherapies

Verrica initiates phase II study of VP-102 for genital warts

BioCryst opens enrollment in phase I study of oral factor D inhibitor BCX-9930

Ziopharm initiates phase II trial of Controlled IL-12 with cemiplimab in recurrent GBM

ImmuPharma reports open-label extension study results for Lupuzor in SLE

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...